Target Name: MCUB
NCBI ID: G55013
Review Report on MCUB Target / Biomarker Content of Review Report on MCUB Target / Biomarker
MCUB
Other Name(s): Mitochondrial calcium uniporter dominant negative subunit beta | mitochondrial calcium uniporter dominant negative beta subunit | Calcium uniporter regulatory subunit MCUb, mitochondrial | CCDC109B | MCUB_HUMAN | coiled-coil domain containing 109B | mitochondrial calcium uniporter regulatory subunit MCUb | FLJ20647 | MCUb | mitochondrial calcium uniporter dominant negative subunit beta | coiled-coil domain-containing protein 109B

MCUB: A Protein Link To A Range of Disorders and Potential Drug Targets

Mitochondrial calcium uniporter (MCUB) is a protein that plays a crucial role in regulating the movement of calcium ions into mitochondria, which are the powerhouses of the cell. Mutations in the MCUB gene have been linked to a range of disorders, including a progressive neurodegenerative disease called Charcot-Marie-Toit disease.

In addition to its role in cell signaling, MCUB is also of interest as a potential drug target. Researchers have identified a number of potential small molecules that can inhibit the activity of MCUB, and are currently exploring these compounds as potential new treatments for a range of diseases.

One of the most promising compounds that has been shown to interact with MCUB is called Z-DSP2. This compound, which is currently being tested in clinical trials for the treatment of Alzheimer's disease, has been shown to significantly reduce the levels of amyloid plaques in the brains of individuals with Alzheimer's, a hallmark of the disease.

Another potential drug that has been shown to interact with MCUB is called TauRex. This compound, which is being developed as a potential treatment for ALS, has been shown to inhibit the activity of MCUB and protect against its accumulation in the brains of individuals with ALS.

In addition to these examples, researchers have also identified a number of other small molecules that have potential to interact with MCUB. These compounds include a variety of natural compounds, such as herbs and spices, as well as synthetic compounds that have been developed for a range of purposes, including the treatment of psychiatric and neurological disorders.

While the potential benefits of these drugs are significant, there are also concerns about their potential side effects. For example, some researchers have suggested that TauRex may have potential to cause neurotoxicity, while others have noted that the use of some natural compounds may be problematic due to their potential interactions with other proteins in the body.

Despite these concerns, however, the potential impact of MCUB on the development of drug treatments for a range of disorders is undeniable. As the research continues to advance, it is likely that new compounds will be identified that can interact with MCUB and have the potential to revolutionize the treatment of a wide range of diseases.

In conclusion, MCUB is a protein that has the potential to be a drug target or biomarker for a range of disorders. While there are currently no approved treatments for any of the disorders associated with MCUB mutations, the potential impact of these mutations on the development of new drugs is significant. Further research is likely to reveal new insights into the role of MCUB in the development of disease and the development of new treatments.

Protein Name: Mitochondrial Calcium Uniporter Dominant Negative Subunit Beta

Functions: Negatively regulates the activity of MCU, the mitochondrial inner membrane calcium uniporter, and thereby modulates calcium uptake into the mitochondrion. Does not form functional calcium channels by itself. Mitochondrial calcium homeostasis plays key roles in cellular physiology and regulates cell bioenergetics, cytoplasmic calcium signals and activation of cell death pathways

The "MCUB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCUB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor | Melanoma-Associated Antigen | Melatonin receptor | MELK